Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer

Rebeca Gonzalez-Pastor, Peter S. Goedegebuure, David T. Curiel

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Ovarian cancer is the leading cause of death among women with gynecological cancer, with an overall 5-year survival rate below 50% due to a lack of specific symptoms, late stage at time of diagnosis and a high rate of recurrence after standard therapy. A better understanding of heterogeneity, genetic mutations, biological behavior and immunosuppression in the tumor microenvironment have allowed the development of more effective therapies based on anti-angiogenic treatments, PARP and immune checkpoint inhibitors, adoptive cell therapies and oncolytic vectors. Oncolytic adenoviruses are commonly used platforms in cancer gene therapy that selectively replicate in tumor cells and at the same time are able to stimulate the immune system. In addition, they can be genetically modified to enhance their potency and overcome physical and immunological barriers. In this review we highlight the challenges of adenovirus-based oncolytic therapies targeting ovarian cancer and outline recent advances to improve their potential in combination with immunotherapies.

Original languageEnglish
Pages (from-to)375-389
Number of pages15
JournalCancer gene therapy
Volume28
Issue number5
DOIs
StatePublished - May 2021

Fingerprint

Dive into the research topics of 'Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer'. Together they form a unique fingerprint.

Cite this